These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16832168)

  • 21. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
    Cheng AY; Leiter LA
    Diabetes Obes Metab; 2008 Sep; 10(9):691-8. PubMed ID: 17593234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
    Barter PJ; Rye KA
    Circulation; 2006 Mar; 113(12):1553-5. PubMed ID: 16567579
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hypolipidemic drugs and diabetes mellitus].
    Bláha V; Mistrík E
    Vnitr Lek; 2009 Apr; 55(4):357-62. PubMed ID: 19449750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates.
    Dominiczak M
    Curr Opin Lipidol; 2009 Feb; 20(1):79-81. PubMed ID: 19106712
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reassessment of cardiovascular risk in diabetes.
    Jaffe JR; Nag SS; Landsman PB; Alexander CM
    Curr Opin Lipidol; 2006 Dec; 17(6):644-52. PubMed ID: 17095909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.
    Saha SA; Kizhakepunnur LG; Bahekar A; Arora RR
    Am Heart J; 2007 Nov; 154(5):943-53. PubMed ID: 17967602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of fibrates on lipid metabolism and the blood coagulation system].
    Paragh G; Balogh Z
    Orv Hetil; 2000 Jan; 141(1):23-6. PubMed ID: 10673854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk and hormone replacement therapy.
    Lawlor DA; Smith GD
    Curr Opin Obstet Gynecol; 2006 Dec; 18(6):658-65. PubMed ID: 17099339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fibrates in the light of large clinical trials].
    Krysiak R; Rudzki H; Handzlik-Orlik G; Gdula-Dymek A; Okopień B
    Pol Merkur Lekarski; 2015 Apr; 38(226):222-7. PubMed ID: 25938391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maximizing scientific knowledge from randomized clinical trials.
    Gustafsson F; Atar D; Pitt B; Zannad F; Pfeffer MA;
    Am Heart J; 2010 Jun; 159(6):937-43. PubMed ID: 20569703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Synthesis and physico-chemical characterisation of some new derivatives of rutoside and clofibric acid].
    Lupaşcu D; Profire L; Dănilă G
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(1):224-7. PubMed ID: 19292111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the Cochrane Review: Fibrates for secondary prevention of cardiovascular disease and stroke.
    Pires da Rosa G; Libânio D; Filipe Azevedo L
    Rev Port Cardiol; 2017 Jan; 36(1):55-58. PubMed ID: 27979321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.